摘要
目的 分析Cyberknife（射波刀）联合细胞因子诱导的杀伤细胞（CIK）多因子诱导自体细胞免疫疗法在肝癌患者治疗中的应用价值.方法 72例肝癌患者行射波刀治疗,其中36例同步CIK细胞免疫治疗,纳入观察组;其余患者纳入对照组.治疗后随访1～6个月,依照WHO肿瘤近期疗效标准评定近期疗效,通过流式细胞术检测治疗前后患者T淋巴细胞、T辅助细胞、自然杀伤细胞（NK）评定免疫功能的变化,综合探讨射波刀联合CIK细胞治疗肝癌的疗效.结果 中位随访期为5个月.两组患者近期治疗有效率分别为72.2%（观察组）和61.1%（对照组）,差异有统计学意义（P＜0.05）;射波刀联合CIK组外周血淋巴细胞亚群均较对照组增强（P＜0.05）.结论 射波刀联合CIK细胞免疫治疗可明显改善患者生存质量,提高肿瘤局部控制率,值得临床深入研究.
Objectivies To investigate the therapeutic efficacy of the combination of Cyberknife and the autologous cellular immunotherapy with cytokine-induced killer （CIK） in the treatment of patients with hepatocellular carcinomas. Methods Enrolled 72 patients with hepatocellular carcinomas were treated with Cyberknife, 36 patients were treated with cellular immunotherapy CIK cells that were included in the observational group, and the remaining 36 patients were included in the control group. These patients were followed up for 1 6 months after treatment to investigate the efficacy of the Cyberknife combined with CIK treatment for hepatocellular carcinomas, including assessment of the short-term effect according to World Health Organization（WHO） and the changes of immune function before and after treatment in patients with T lymphocytes, T helper cells, and natural kill cells（NK） by flow cytometry. Resuits The median follow-up period was 5 months. The effective rate of the two groups were 72. 2% （ observational group） and 61.1% （control group） （ P 〈 0. 05）. The subsets of T lymphocytes, helper T cells, and NK cells of patients treated with the combination of Cyberknife and CIK were significantly higher than the control group （ P 〈 0. 05）. Conclusions CIK immunotherapy combined with Cyberknife comprehensively optimized the physical and biological effects of cancer treatment. This method is worthy of clinical applica- tion.
出处
《中国医师杂志》
CAS
2014年第1期13-16,共4页
Journal of Chinese Physician
基金
国家高技术研究发展计划（863计划）
